Table 2.
Bupropion and venlafaxine misuse/abuse-; dependence-; withdrawal and remaining-related ADRs': occurrence and proportional reporting ratio (PRR).
| Bupropion ADRs | No. of reactions ADRs | Proportion of bupropion ADRs | Bupropion vs. venlafaxine PRR |
|---|---|---|---|
| Misuse/abuse-related ADRs (A1) | 1,558 | 0.075 | 1.50 |
| Dependence–related ADRs (A2) | 674 | 0.032 | 0.92 (reverse: 1.09) |
| Withdrawal-related ADRs (A3) | 299 | 0.014 | 0.77 (reverse: 1.30) |
| Other Adverse Events (B) | 18,189 | 0.878 | |
| Total (A1+A2+A3 +B) | 20,720 | 1 | |
| Venlafaxine ADRs | No. of reactions ADRs | Proportion of venlafaxine ADRs | |
| Misuse/abuse-related ADRs (C1) | 2,361 | 0.05 | |
| Dependence–related ADRs (C2) | 1,710 | 0.036 | |
| Withdrawal syndrome-related ADRs (C3) | 914 | 0.019 | |
| Other adverse events (D) | 42,531 | 0.895 | |
| Total (C1+C2+C3+D) | 47,516 | 1 |